BRIEF-Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc

Oct 18 (Reuters) – Zentalis Pharmaceuticals, Inc. : * ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST OVERALL SURVIVAL DATA FOR AZENOSERTIB FROM DENALI PART 1B PUBLISHED IN ESMO CONGRESS 2026 ABSTRACT *

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)